Laurie Conklin MD is a Senior Director in the Child Health Innovation and Leadership Department within the Office of the Chief Medical Officer at Johnson & Johnson Innovative Medicine. She provides child/adolescent-relevant strategic support to a variety of teams, including clinical, regulatory, operations, medical affairs, and business development. Prior to this role, Dr. Conklin led pediatric Stelara programs and IBD pediatric strategy within Janssen Immunology. She led the development of a playbook on rare disease drug development for Janssen Immunology R&D. Before joining Janssen, Dr. Conklin worked with ReveraGen BioPharma on Phase 2 trials of Agamree, a therapy recently approved in the US and EU for Duchenne muscular dystrophy. She was the recipient of a Pediatric Pharmacology grant from NICHD to study biomarkers in pediatric inflammatory diseases and has experience at the FDA as a Medical Officer in Pediatrics at CDER. Dr. Conklin was a practicing pediatric gastroenterologist for over 11 years, and director of the IBD Program at Children’s National Hospital from 2011-2018. After completing Pediatrics residency and chief residency at New York Presbyterian-Weill Cornell Medical Center, Dr. Conklin completed a fellowship in Pediatric Gastroenterology Hepatology, and Nutrition at Johns Hopkins, followed by a graduate certificate in Clinical and Translational Science from the George Washington University School of Medicine.